Price
$83.89+16.21%Social Signal Score
Analyst Ratings
13 analystsRevenue
$189.95M+10134.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Waleed H. Hassanein
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 898
- Beta
- 1.88
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 2.62
Financials
Revenue
$189.95M+10134.3%Net Income
$14.68MEBITDA
$26.63MFree Cash Flow
$10.22MEPS (diluted)
$0.41Shares Outstanding (diluted)
40.71M+776.2%Operating Expenses
$89.46MCash & Debt
$472.68MRevenue by Segment (annual)
$605.49MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $605.49M | $190.29M | $5.60 |
| 2024 | $441.54M | $35.46M | $1.07 |
| 2023 | $241.62M | $-25.03M | $-0.77 |
| 2022 | $93.46M | $-36.23M | $-1.23 |
| 2021 | $30.26M | $-44.22M | $-1.60 |
| 2020 | $25.64M | $-28.75M | $-1.16 |
| 2019 | $23.60M | $-33.55M | $-2.36 |
| 2018 | $13.02M | $-23.76M | $-1.23 |
| 2017 | $7.68M | $-20.82M | $-1.44 |
| 2016 | $6.21M | $-24.07M | $-1.66 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $8.23
- Implied price
- $180.95
- Return from $79.80
- 17.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $89.97 — today's price is already 11.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -2.0% | 0.3% | 3.8% | 6.9% | 9.7% | 12.2% |
| 3.0% | 5.4% | 9.1% | 12.3% | 15.2% | 17.9% |
| 8.0% | 10.5% | 14.4% | 17.8% | 20.8% | 23.6% |
| 13.0% | 15.6% | 19.7% | 23.2% | 26.4% | 29.3% |
| 18.0% | 20.8% | 25.0% | 28.7% | 32.0% | 35.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (4)
- Newszacks.com·32d ago·Positive
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure? TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
View source ↗ - Newszacks.com·32d ago·Neutral
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report? TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·35d ago·Neutral
TransMedics to Present at Upcoming September Investor Conferences ANDOVER, Mass., Aug. 31, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
View source ↗ - Newsmarketbeat.com·49d ago·Neutral
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion TransMedics Group NASDAQ: TMDX outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.29 per share
Typical surprise +39.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.44 vs $0.50miss
- Tue, May 5$0.30 vs $0.62miss
- Tue, Feb 24$0.57 vs $0.41beat
- Wed, Oct 29$0.66 vs $0.37beat
- Wed, Jul 30$0.92 vs $0.48beat
- Thu, May 8$0.70 vs $0.29beat
Estimates and results for TMDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TMDX officers and directors.
- Bought
- $3.1m
- Sold
- $7.9m
5 trades
23 trades
- Weill Davidbought
- Gunderson Thomas J.sold
- Lovell Stephaniesold
- Weill Davidsold
- Hernandez Gerardosold
- Hernandez Gerardosold
- Ranganath Anil P.sold
- Corcoran Nicholassold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TMDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.